In surgical pathology, the patient is still under surgery while a pathologist makes a rapid, preliminary diagnosis on fresh tissue. This can be done in under 10 minutes, but typically takes 20-30 in practice -- the bulk of which time is spent flash-freezing and sectioning. Pathologists have only a few minutes to review after prep, so any digital augmentation technology must run on the order of a few minutes to be of use in guiding the surgery. This guidance may be crucial because many tumors cannot be characterized ahead of time due to the lack of non-invasive diagnostic tools (the most promising is gene profiling of bloodborne cells, but that is very challenging due to low circulating concentrations). Tumor type and grade are a large factor in a surgeon’s aggressiveness-vs-risk calculation, and this is especially true in brain tumors where cognitive damage poses a quality-of-life risk which must be weighed against potential survival gains.
(not a pathologist, but I've done research, classifier, and software dev in the field -- very small, hands-on lab, so spent a huge amount of time in frozen section, OR, and with paths reviewing sections)
I trust that science, research and ongoing work will end up providing interesting results, but many many startups will burn their cash before being able to provide real world usage services.
Like you said, there are LOTs of challenges here. Certainly not a "low hanging fruit", not that a profitable business either since most countries will squash costs anywhere they can because the health cost keeps growing, and a very difficult legal environment to deal with.
However, I am very thankful for your hard work and will to push toward a better future for health.